Terry L Riss

Summary

Affiliation: Promega Corporation
Country: USA

Publications

  1. ncbi Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays
    Terry L Riss
    Cellular Analysis, Promega Corporation, Madison, WI 53575, USA
    Assay Drug Dev Technol 2:51-62. 2004
  2. ncbi Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death
    Terry L Riss
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 740:103-14. 2011
  3. ncbi Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format
    Richard A Moravec
    Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
    Anal Biochem 387:294-302. 2009
  4. ncbi Multiplex caspase activity and cytotoxicity assays
    Andrew L Niles
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:151-62. 2008
  5. ncbi A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers
    Andrew L Niles
    Promega Corp, Madison, WI 53711, USA
    Anal Biochem 366:197-206. 2007
  6. ncbi Bioluminescent assays for ADMET
    James J Cali
    Promega Corp, 2800 Woods Hollow Road, Madison, WI 53711, USA
    Expert Opin Drug Metab Toxicol 4:103-20. 2008
  7. ncbi A bioluminescent assay for monoamine oxidase activity
    Michael P Valley
    Promega Corporation, Madison, WI 53711, USA
    Anal Biochem 359:238-46. 2006
  8. ncbi New bioluminogenic substrates for monoamine oxidase assays
    Wenhui Zhou
    Promega Biosciences, Inc, 277 Granada Drive, San Luis Obispo, California 93401, USA
    J Am Chem Soc 128:3122-3. 2006
  9. ncbi Caspase activity assays
    Andrew L Niles
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:137-50. 2008
  10. ncbi Homogeneous, bioluminescent proteasome assays
    Martha A O'Brien
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:163-81. 2008

Detail Information

Publications11

  1. ncbi Use of multiple assay endpoints to investigate the effects of incubation time, dose of toxin, and plating density in cell-based cytotoxicity assays
    Terry L Riss
    Cellular Analysis, Promega Corporation, Madison, WI 53575, USA
    Assay Drug Dev Technol 2:51-62. 2004
    ..These results illustrate the importance of understanding the kinetics and mechanism of cell death of each in vitro model system as prerequisites for choosing the most appropriate assay method...
  2. ncbi Cytotoxicity testing: measuring viable cells, dead cells, and detecting mechanism of cell death
    Terry L Riss
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 740:103-14. 2011
    ..Data analysis from the measurement of three marker protease activities from the same sample provides a useful tool to help uncover the mechanism of cell death and can serve as an internal control to help identify assay artifacts...
  3. ncbi Cell-based bioluminescent assays for all three proteasome activities in a homogeneous format
    Richard A Moravec
    Promega Corporation, 2800 Woods Hollow Road, Madison, WI 53711, USA
    Anal Biochem 387:294-302. 2009
    ..These cell-based proteasome assays are direct, simple, and sensitive, making them ideal for high-throughput screening...
  4. ncbi Multiplex caspase activity and cytotoxicity assays
    Andrew L Niles
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:151-62. 2008
    ..Furthermore, multiplexing caspase activity assays with viability and/or cytotoxicity assays can support conclusions regarding cytotoxic mechanism and provide normalization that may help correct for differences in cell number...
  5. ncbi A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers
    Andrew L Niles
    Promega Corp, Madison, WI 53711, USA
    Anal Biochem 366:197-206. 2007
    ..Ratiometric measurement of viable and dead cells in the same sample provides an internal control that can be used to normalize data from other cell-based assays...
  6. ncbi Bioluminescent assays for ADMET
    James J Cali
    Promega Corp, 2800 Woods Hollow Road, Madison, WI 53711, USA
    Expert Opin Drug Metab Toxicol 4:103-20. 2008
    ..The bioluminescent ADMET assays are rapid and sensitive, amenable to automated high-throughput applications and offer significant advantages over alternative methods...
  7. ncbi A bioluminescent assay for monoamine oxidase activity
    Michael P Valley
    Promega Corporation, Madison, WI 53711, USA
    Anal Biochem 359:238-46. 2006
    ..Other advantages of this bioluminescent assay over comparable fluorescent assays are discussed...
  8. ncbi New bioluminogenic substrates for monoamine oxidase assays
    Wenhui Zhou
    Promega Biosciences, Inc, 277 Granada Drive, San Luis Obispo, California 93401, USA
    J Am Chem Soc 128:3122-3. 2006
    ..This design strategy should be applicable to fluorogenic MAO substrates and could broaden the structural requirements of substrates for other enzyme assays...
  9. ncbi Caspase activity assays
    Andrew L Niles
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:137-50. 2008
    ..The highlighted techniques in this chapter are cost efficient and allow for the rapid exploration of thousands of combinations and conditions...
  10. ncbi Homogeneous, bioluminescent proteasome assays
    Martha A O'Brien
    Promega Corporation, Madison, WI, USA
    Methods Mol Biol 414:163-81. 2008
    ..The bioluminescent, coupled-enzyme format enables sensitive and rapid protease assays ideal for inhibitor screening...
  11. ncbi In vitro viability and cytotoxicity testing and same-well multi-parametric combinations for high throughput screening
    Andrew L Niles
    Research Department, Promega Corporation, 2800 Woods Hollow Road, Madison, WI, USA
    Curr Chem Genomics 3:33-41. 2009
    ..Lastly, we discuss the advantages of combining specific HTS compatible assays into multi-parametric, same-well formats...